Ascendis Pharma A/S (FRA:A71)
Germany · Delayed Price · Currency is EUR | Market Cap | 11.68B +49.0% |
| Revenue (ttm) | 646.55M +97.5% |
| Net Income | -232.94M |
| EPS | -3.87 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 70.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 12 |
| Open | 186.00 |
| Previous Close | 184.00 |
| Day's Range | 186.00 - 186.00 |
| 52-Week Range | 115.00 - 197.00 |
| Beta | n/a |
| RSI | 52.43 |
| Earnings Date | Feb 11, 2026 |
About Ascendis Pharma
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses o... [Read more]
Financial Performance
In 2024, Ascendis Pharma's revenue was 363.64 million, an increase of 36.34% compared to the previous year's 266.72 million. Losses were -378.08 million, -21.47% less than in 2023.
Financial StatementsNews
Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down...
Ascendis Pharma A/S at JPMorgan Healthcare Conference Transcript
Ascendis Pharma A/S at JPMorgan Healthcare Conference Transcript
Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ascendis Pharma (ASND) Focuses on Core Plans Amidst Market Conditions
Ascendis Pharma (ASND) Focuses on Core Plans Amidst Market Conditions
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascen...
Ascendis Pharma (ASND) Receives Increased Price Target from Wells Fargo | ASND Stock News
Ascendis Pharma (ASND) Receives Increased Price Target from Wells Fargo | ASND Stock News
Ascendis Confirms Durable Growth Benefits In Achondroplasia In COACH Trial
(RTTNews) - Ascendis Pharma A/S (ASND) announced positive topline data from the Week 52 COACH Phase 2 trial evaluating once-weekly TransCon CNP in combination with TransCon hGH in pediatric patients w...
Ascendis Pharma (ASND) Reports Positive Phase 2 Trial Results in Achondroplasia
Ascendis Pharma (ASND) Reports Positive Phase 2 Trial Results in Achondroplasia
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
– Once-weekly TransCon ® CNP and TransCon ® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-p...
Analyst Reiterates Buy Rating for Ascendis Pharma (ASND) with $325 Price Target | ASND Stock News
Analyst Reiterates Buy Rating for Ascendis Pharma (ASND) with $325 Price Target | ASND Stock News
Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference ...
Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 16.0% on an annualized basis producing an average annual return of 28.84%. Currently, Ascendis Pharma has a market...
Here's My Prediction For Who Could Acquire Ascendis Pharma
Ascendis Pharma (ASND) Shares Surge Amid Takeover Speculation
Ascendis Pharma (ASND) Shares Surge Amid Takeover Speculation
$100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today
Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 16.13% on an annualized basis producing an average annual return of 28.9%. Currently, Ascendis Pharma has a market...
Ascendis Pharma (ASND) Faces Acquisition Rumor
Ascendis Pharma (ASND) Faces Acquisition Rumor
Ascendis Pharma gains amid takeover speculation
Looking Into Ascendis Pharma AS's Recent Short Interest
Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has risen 10.27% since its last report. According to exchange reported data, there are now 3.30 million shares sold short , whic...
March 2026 Options Now Available For Ascendis Pharma (ASND)
Investors in Ascendis Pharma A/S (Symbol: ASND) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pa...
Eight stock picks to play one of the healthiest corners of the market
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull mar...
Stifel Raises Price Target for Ascendis Pharma (ASND) to $256 | ASND Stock News
Stifel Raises Price Target for Ascendis Pharma (ASND) to $256 | ASND Stock News
High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth
The Touchstone Mid Cap Growth Fund outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended September 30, 2025. From a factor perspective, the Fund's overweight exposure to ...
Monolithic Power, Ascendis Pharma And More: CNBC's 'Final Trades'
On CNBC's “ Halftime Report Final Trades ,” on Monday, Amy Raskin , chief investment officer at Chevy Chase Trust, named Ascendis Pharma A/S (NASDAQ: ASND) as her final trade . According to recent ne...